MENU

Leading brokers name 3 ASX shares to sell

On Monday I had a look at three shares that have found favour with brokers this week and been given the much-coveted buy rating.

Today I thought I would look at the shares that have fallen out of favour with brokers and are the unlucky recipients of the dreaded sell rating.

Three that caught my eye are listed below:

Asaleo Care Ltd (ASX: AHY)

According to a note out of Credit Suisse, its analysts have downgraded the personal care products company’s shares to an underperform rating from neutral. The broker has also reduced its price target on Asaleo Care’s shares to $1.30 from $1.35 after revising down its earnings forecasts. Credit Suisse made the revisions after factoring in rising raw material costs. I would agree with Credit Suisse on Asaleo Care and think there are far better options in the retail sector for investors to choose from.

Boral Limited (ASX: BLD)

Another note out of Credit Suisse reveals that it has also downgraded this building materials company’s shares from neutral to an underperform rating. The broker has slashed the price target on Boral’s shares to $6.40 from $7.45. Credit Suisse has made the move largely on concerns that the market is expecting too much growth from its North American operations. While I do agree with Credit Suisse, I’m not sure I would be rushing to sell its shares just yet. After all, they are currently trading at a 52-week low, are down almost 25% from their 52-week high, and below the broker’s target price.

Medibank Private Ltd (ASX: MPL)

Analysts at Goldman Sachs have retained their sell rating and $2.70 price target on the private health insurer’s shares following the release of APRA’s private health insurance (PHI) industry data for the March 2018 quarter. That data revealed a further 0.3% decline in policyholder growth, leading to the proportion of the population covered by hospital PHI falling to 45.5%. Goldman remains negative on the PHI industry due largely to affordability headwinds and political uncertainty. I agree with Goldman on this one and think investors ought to stay clear of Medibank Private for the time being.

While those shares may be the shares to sell, these top shares are the ones to buy in my opinion. I'm tipping them to beat the market in FY 2019.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!